Serveur d'exploration sur la rapamycine et les champignons

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis.

Identifieur interne : 000F82 ( Main/Exploration ); précédent : 000F81; suivant : 000F83

Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis.

Auteurs : Hui Yin [République populaire de Chine] ; Xiangyong Li ; Bobin Zhang ; Tao Liu ; Baohong Yuan ; Qian Ni ; Shilian Hu ; Hongbiao Gu

Source :

RBID : pubmed:23480027

Descripteurs français

English descriptors

Abstract

Inflammatory bowel disease is characterized by dysregulated immune responses in inflamed intestine, with dominance of interleukin-17 (IL-17)--producing cells and deficiency of regulatory T (Treg) cells. The aim of this study was to investigate the effect and mechanisms of sirolimus, an inhibitor of the mammalian target of rapamycin, on immune responses in a murine model of Crohn's disease. Murine colitis was induced by intrarectal administration of 2,4,6-trinitrobenzene sulphonic acid at day 0. Mice were then treated intraperitoneally with sirolimus daily for 3 days. The gross and histological appearances of the colon and the numbers, phenotype and cytokine production of lymphocytes were compared with these characteristics in a control group. Sirolimus treatment significantly decreased all macroscopic, microscopic and histopathological parameters of colitis that were analysed. The therapeutic effects of sirolimus were associated with a down-regulation of pro-inflammatory cytokines tumour necrosis factor-α, IL-6 and IL-17A. Intriguingly, sirolimus administration resulted in a prominent up-regulation of the regulatory cytokine transforming growth factor-β. Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice. Simultaneously, sirolimus treatment led to a significant reduction in the number of CD4+ IL-17A+ T cells in the mesenteric lymph node cells as well as IL-17A production in mesenteric lymph node cells. Therefore, sirolimus may offer a promising new therapeutic strategy for the treatment of inflammatory bowel disease.

DOI: 10.1111/imm.12096
PubMed: 23480027
PubMed Central: PMC3719066


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis.</title>
<author>
<name sortKey="Yin, Hui" sort="Yin, Hui" uniqKey="Yin H" first="Hui" last="Yin">Hui Yin</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Microbiology and Immunology, Guangdong Pharmaceutical University, Guangzhou, China. huiyin0103@yahoo.com.cn</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Microbiology and Immunology, Guangdong Pharmaceutical University, Guangzhou</wicri:regionArea>
<placeName>
<settlement type="city">Jiangmen</settlement>
<region type="province">Guangdong</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Li, Xiangyong" sort="Li, Xiangyong" uniqKey="Li X" first="Xiangyong" last="Li">Xiangyong Li</name>
</author>
<author>
<name sortKey="Zhang, Bobin" sort="Zhang, Bobin" uniqKey="Zhang B" first="Bobin" last="Zhang">Bobin Zhang</name>
</author>
<author>
<name sortKey="Liu, Tao" sort="Liu, Tao" uniqKey="Liu T" first="Tao" last="Liu">Tao Liu</name>
</author>
<author>
<name sortKey="Yuan, Baohong" sort="Yuan, Baohong" uniqKey="Yuan B" first="Baohong" last="Yuan">Baohong Yuan</name>
</author>
<author>
<name sortKey="Ni, Qian" sort="Ni, Qian" uniqKey="Ni Q" first="Qian" last="Ni">Qian Ni</name>
</author>
<author>
<name sortKey="Hu, Shilian" sort="Hu, Shilian" uniqKey="Hu S" first="Shilian" last="Hu">Shilian Hu</name>
</author>
<author>
<name sortKey="Gu, Hongbiao" sort="Gu, Hongbiao" uniqKey="Gu H" first="Hongbiao" last="Gu">Hongbiao Gu</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23480027</idno>
<idno type="pmid">23480027</idno>
<idno type="doi">10.1111/imm.12096</idno>
<idno type="pmc">PMC3719066</idno>
<idno type="wicri:Area/Main/Corpus">001052</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001052</idno>
<idno type="wicri:Area/Main/Curation">001052</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001052</idno>
<idno type="wicri:Area/Main/Exploration">001052</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis.</title>
<author>
<name sortKey="Yin, Hui" sort="Yin, Hui" uniqKey="Yin H" first="Hui" last="Yin">Hui Yin</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Microbiology and Immunology, Guangdong Pharmaceutical University, Guangzhou, China. huiyin0103@yahoo.com.cn</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Microbiology and Immunology, Guangdong Pharmaceutical University, Guangzhou</wicri:regionArea>
<placeName>
<settlement type="city">Jiangmen</settlement>
<region type="province">Guangdong</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Li, Xiangyong" sort="Li, Xiangyong" uniqKey="Li X" first="Xiangyong" last="Li">Xiangyong Li</name>
</author>
<author>
<name sortKey="Zhang, Bobin" sort="Zhang, Bobin" uniqKey="Zhang B" first="Bobin" last="Zhang">Bobin Zhang</name>
</author>
<author>
<name sortKey="Liu, Tao" sort="Liu, Tao" uniqKey="Liu T" first="Tao" last="Liu">Tao Liu</name>
</author>
<author>
<name sortKey="Yuan, Baohong" sort="Yuan, Baohong" uniqKey="Yuan B" first="Baohong" last="Yuan">Baohong Yuan</name>
</author>
<author>
<name sortKey="Ni, Qian" sort="Ni, Qian" uniqKey="Ni Q" first="Qian" last="Ni">Qian Ni</name>
</author>
<author>
<name sortKey="Hu, Shilian" sort="Hu, Shilian" uniqKey="Hu S" first="Shilian" last="Hu">Shilian Hu</name>
</author>
<author>
<name sortKey="Gu, Hongbiao" sort="Gu, Hongbiao" uniqKey="Gu H" first="Hongbiao" last="Gu">Hongbiao Gu</name>
</author>
</analytic>
<series>
<title level="j">Immunology</title>
<idno type="eISSN">1365-2567</idno>
<imprint>
<date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals (MeSH)</term>
<term>Anti-Inflammatory Agents (administration & dosage)</term>
<term>Anti-Inflammatory Agents (pharmacology)</term>
<term>CD4 Lymphocyte Count (MeSH)</term>
<term>Cells, Cultured (MeSH)</term>
<term>Colitis (chemically induced)</term>
<term>Colitis (immunology)</term>
<term>Colitis (pathology)</term>
<term>Colitis (prevention & control)</term>
<term>Colon (drug effects)</term>
<term>Colon (immunology)</term>
<term>Colon (pathology)</term>
<term>Disease Models, Animal (MeSH)</term>
<term>Forkhead Transcription Factors (metabolism)</term>
<term>Immunosuppressive Agents (administration & dosage)</term>
<term>Immunosuppressive Agents (pharmacology)</term>
<term>Inflammation Mediators (metabolism)</term>
<term>Injections, Intraperitoneal (MeSH)</term>
<term>Interleukin-17 (metabolism)</term>
<term>Interleukin-6 (metabolism)</term>
<term>Lymph Nodes (drug effects)</term>
<term>Lymph Nodes (immunology)</term>
<term>Male (MeSH)</term>
<term>Mice (MeSH)</term>
<term>Mice, Inbred BALB C (MeSH)</term>
<term>Phenotype (MeSH)</term>
<term>Sirolimus (administration & dosage)</term>
<term>Sirolimus (pharmacology)</term>
<term>Th17 Cells (drug effects)</term>
<term>Th17 Cells (immunology)</term>
<term>Time Factors (MeSH)</term>
<term>Transforming Growth Factor beta (metabolism)</term>
<term>Trinitrobenzenesulfonic Acid (MeSH)</term>
<term>Tumor Necrosis Factor-alpha (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Acide 2,4,6-trinitro-benzènesulfonique (MeSH)</term>
<term>Animaux (MeSH)</term>
<term>Anti-inflammatoires (administration et posologie)</term>
<term>Anti-inflammatoires (pharmacologie)</term>
<term>Cellules Th17 (effets des médicaments et des substances chimiques)</term>
<term>Cellules Th17 (immunologie)</term>
<term>Cellules cultivées (MeSH)</term>
<term>Colite (anatomopathologie)</term>
<term>Colite (immunologie)</term>
<term>Colite (induit chimiquement)</term>
<term>Colite (prévention et contrôle)</term>
<term>Côlon (anatomopathologie)</term>
<term>Côlon (effets des médicaments et des substances chimiques)</term>
<term>Côlon (immunologie)</term>
<term>Facteur de croissance transformant bêta (métabolisme)</term>
<term>Facteur de nécrose tumorale alpha (métabolisme)</term>
<term>Facteurs de transcription Forkhead (métabolisme)</term>
<term>Facteurs temps (MeSH)</term>
<term>Immunosuppresseurs (administration et posologie)</term>
<term>Immunosuppresseurs (pharmacologie)</term>
<term>Injections péritoneales (MeSH)</term>
<term>Interleukine-17 (métabolisme)</term>
<term>Interleukine-6 (métabolisme)</term>
<term>Modèles animaux de maladie humaine (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Médiateurs de l'inflammation (métabolisme)</term>
<term>Noeuds lymphatiques (effets des médicaments et des substances chimiques)</term>
<term>Noeuds lymphatiques (immunologie)</term>
<term>Numération des lymphocytes CD4 (MeSH)</term>
<term>Phénotype (MeSH)</term>
<term>Sirolimus (administration et posologie)</term>
<term>Sirolimus (pharmacologie)</term>
<term>Souris (MeSH)</term>
<term>Souris de lignée BALB C (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Anti-Inflammatory Agents</term>
<term>Immunosuppressive Agents</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Forkhead Transcription Factors</term>
<term>Inflammation Mediators</term>
<term>Interleukin-17</term>
<term>Interleukin-6</term>
<term>Transforming Growth Factor beta</term>
<term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Anti-Inflammatory Agents</term>
<term>Immunosuppressive Agents</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Anti-inflammatoires</term>
<term>Immunosuppresseurs</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Colite</term>
<term>Côlon</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en">
<term>Colitis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Colon</term>
<term>Lymph Nodes</term>
<term>Th17 Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Cellules Th17</term>
<term>Côlon</term>
<term>Noeuds lymphatiques</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Cellules Th17</term>
<term>Colite</term>
<term>Côlon</term>
<term>Noeuds lymphatiques</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Colitis</term>
<term>Colon</term>
<term>Lymph Nodes</term>
<term>Th17 Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr">
<term>Colite</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Facteur de croissance transformant bêta</term>
<term>Facteur de nécrose tumorale alpha</term>
<term>Facteurs de transcription Forkhead</term>
<term>Interleukine-17</term>
<term>Interleukine-6</term>
<term>Médiateurs de l'inflammation</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Colitis</term>
<term>Colon</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Anti-inflammatoires</term>
<term>Immunosuppresseurs</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Colitis</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr">
<term>Colite</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>CD4 Lymphocyte Count</term>
<term>Cells, Cultured</term>
<term>Disease Models, Animal</term>
<term>Injections, Intraperitoneal</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Phenotype</term>
<term>Time Factors</term>
<term>Trinitrobenzenesulfonic Acid</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Acide 2,4,6-trinitro-benzènesulfonique</term>
<term>Animaux</term>
<term>Cellules cultivées</term>
<term>Facteurs temps</term>
<term>Injections péritoneales</term>
<term>Modèles animaux de maladie humaine</term>
<term>Mâle</term>
<term>Numération des lymphocytes CD4</term>
<term>Phénotype</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Inflammatory bowel disease is characterized by dysregulated immune responses in inflamed intestine, with dominance of interleukin-17 (IL-17)--producing cells and deficiency of regulatory T (Treg) cells. The aim of this study was to investigate the effect and mechanisms of sirolimus, an inhibitor of the mammalian target of rapamycin, on immune responses in a murine model of Crohn's disease. Murine colitis was induced by intrarectal administration of 2,4,6-trinitrobenzene sulphonic acid at day 0. Mice were then treated intraperitoneally with sirolimus daily for 3 days. The gross and histological appearances of the colon and the numbers, phenotype and cytokine production of lymphocytes were compared with these characteristics in a control group. Sirolimus treatment significantly decreased all macroscopic, microscopic and histopathological parameters of colitis that were analysed. The therapeutic effects of sirolimus were associated with a down-regulation of pro-inflammatory cytokines tumour necrosis factor-α, IL-6 and IL-17A. Intriguingly, sirolimus administration resulted in a prominent up-regulation of the regulatory cytokine transforming growth factor-β. Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice. Simultaneously, sirolimus treatment led to a significant reduction in the number of CD4+ IL-17A+ T cells in the mesenteric lymph node cells as well as IL-17A production in mesenteric lymph node cells. Therefore, sirolimus may offer a promising new therapeutic strategy for the treatment of inflammatory bowel disease.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23480027</PMID>
<DateCompleted>
<Year>2013</Year>
<Month>09</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1365-2567</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>139</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Immunology</Title>
<ISOAbbreviation>Immunology</ISOAbbreviation>
</Journal>
<ArticleTitle>Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis.</ArticleTitle>
<Pagination>
<MedlinePgn>494-502</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/imm.12096</ELocationID>
<Abstract>
<AbstractText>Inflammatory bowel disease is characterized by dysregulated immune responses in inflamed intestine, with dominance of interleukin-17 (IL-17)--producing cells and deficiency of regulatory T (Treg) cells. The aim of this study was to investigate the effect and mechanisms of sirolimus, an inhibitor of the mammalian target of rapamycin, on immune responses in a murine model of Crohn's disease. Murine colitis was induced by intrarectal administration of 2,4,6-trinitrobenzene sulphonic acid at day 0. Mice were then treated intraperitoneally with sirolimus daily for 3 days. The gross and histological appearances of the colon and the numbers, phenotype and cytokine production of lymphocytes were compared with these characteristics in a control group. Sirolimus treatment significantly decreased all macroscopic, microscopic and histopathological parameters of colitis that were analysed. The therapeutic effects of sirolimus were associated with a down-regulation of pro-inflammatory cytokines tumour necrosis factor-α, IL-6 and IL-17A. Intriguingly, sirolimus administration resulted in a prominent up-regulation of the regulatory cytokine transforming growth factor-β. Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice. Simultaneously, sirolimus treatment led to a significant reduction in the number of CD4+ IL-17A+ T cells in the mesenteric lymph node cells as well as IL-17A production in mesenteric lymph node cells. Therefore, sirolimus may offer a promising new therapeutic strategy for the treatment of inflammatory bowel disease.</AbstractText>
<CopyrightInformation>© 2013 John Wiley & Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yin</LastName>
<ForeName>Hui</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology, Guangdong Pharmaceutical University, Guangzhou, China. huiyin0103@yahoo.com.cn</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Xiangyong</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Bobin</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Tao</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yuan</LastName>
<ForeName>Baohong</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ni</LastName>
<ForeName>Qian</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Shilian</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gu</LastName>
<ForeName>Hongbiao</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Immunology</MedlineTA>
<NlmUniqueID>0374672</NlmUniqueID>
<ISSNLinking>0019-2805</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C498833">Foxp3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C098680">Il17a protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>8T3HQG2ZC4</RegistryNumber>
<NameOfSubstance UI="D014302">Trinitrobenzenesulfonic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003092" MajorTopicYN="N">Colitis</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051858" MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007274" MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058504" MajorTopicYN="N">Th17 Cells</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014302" MajorTopicYN="N">Trinitrobenzenesulfonic Acid</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">T helper type 17 cells</Keyword>
<Keyword MajorTopicYN="N">colitis</Keyword>
<Keyword MajorTopicYN="N">inflammation</Keyword>
<Keyword MajorTopicYN="N">regulatory T cells</Keyword>
<Keyword MajorTopicYN="N">sirolimus</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2012</Year>
<Month>12</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2013</Year>
<Month>02</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2013</Year>
<Month>02</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2013</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2013</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2013</Year>
<Month>9</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">23480027</ArticleId>
<ArticleId IdType="doi">10.1111/imm.12096</ArticleId>
<ArticleId IdType="pmc">PMC3719066</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Leukoc Biol. 2009 Oct;86(4):959-69</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19477911</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2009;4(6):e5994</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19543393</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Opin Pharmacol. 2009 Dec;9(6):702-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19674937</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Immunol. 2010 Jan;30(1):80-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19936899</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nephrol Dial Transplant. 2010 Mar;25(3):710-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19903662</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Annu Rev Immunol. 2010;28:573-621</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20192811</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Immunol. 2010 Sep;47(15):2443-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20638132</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunity. 2010 Sep 24;33(3):301-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20870173</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Transplantation. 2011 Jan 27;91(2):199-206</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21239962</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Immunol. 2011 Apr;12(4):295-303</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21358638</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2011 Jun 16;474(7351):298-306</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21677746</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2011 Aug 25;118(8):2342-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21734238</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2012;7(3):e30985</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22427801</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mucosal Immunol. 2012 May;5(3):240-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22354322</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunology. 2012 Jun;136(2):115-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22348589</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Immunol. 2012 May;12(5):325-38</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22517423</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Transplant. 2012 Jun;12(6):1441-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22300641</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neuroimmunol. 2012 Sep 15;250(1-2):9-17</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22673299</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Discov Med. 2012 Oct;14(77):253-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23114581</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2000 May 1;164(9):4878-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10779797</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cytokine. 2000 Jul;12(7):1092-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10880256</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lupus. 2000;9(8):589-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11035433</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gut. 2003 Jan;52(1):65-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12477762</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2003 Feb 13;348(7):601-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12584368</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Immunol. 2003 Apr;4(4):330-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12612578</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 2003 Dec 15;198(12):1875-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14676299</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2005 Jun 15;105(12):4743-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15746082</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2006 Jul 1;177(1):566-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16785554</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Clin Pract Gastroenterol Hepatol. 2006 Jul;3(7):390-407</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16819502</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunol Rev. 2006 Aug;212:256-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16903919</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2006 Sep 22;126(6):1121-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16990136</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2007 Jan 1;178(1):320-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17182569</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 2006 Dec 25;203(13):2785-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17130300</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Inflamm Bowel Dis. 2007 Feb;13(2):191-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17206665</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2007 Jun;132(7):2359-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17570211</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Immunol. 2007 Aug;7(8):585-98</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17653126</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Gastroenterol. 2007 Sep;102(9):2058-69</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17561966</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int Immunopharmacol. 2007 Dec 15;7(13):1819-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17996694</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Immunol. 2007 Dec;8(12):1390-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17994024</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neuroimmunol. 2008 May 30;196(1-2):124-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18417225</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gastroenterology. 2009 Apr;136(4):1182-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19249397</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Immunol. 2009 May;9(5):324-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19390566</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Allergy Clin Immunol. 2009 May;123(5):997-1003</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19362732</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes. 2009 Jun;58(6):1302-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19289457</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunity. 2009 Jun 19;30(6):899-911</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19464196</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Gastroenterol. 2009;44(11):1097-108</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19802731</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>République populaire de Chine</li>
</country>
<region>
<li>Guangdong</li>
</region>
<settlement>
<li>Jiangmen</li>
</settlement>
</list>
<tree>
<noCountry>
<name sortKey="Gu, Hongbiao" sort="Gu, Hongbiao" uniqKey="Gu H" first="Hongbiao" last="Gu">Hongbiao Gu</name>
<name sortKey="Hu, Shilian" sort="Hu, Shilian" uniqKey="Hu S" first="Shilian" last="Hu">Shilian Hu</name>
<name sortKey="Li, Xiangyong" sort="Li, Xiangyong" uniqKey="Li X" first="Xiangyong" last="Li">Xiangyong Li</name>
<name sortKey="Liu, Tao" sort="Liu, Tao" uniqKey="Liu T" first="Tao" last="Liu">Tao Liu</name>
<name sortKey="Ni, Qian" sort="Ni, Qian" uniqKey="Ni Q" first="Qian" last="Ni">Qian Ni</name>
<name sortKey="Yuan, Baohong" sort="Yuan, Baohong" uniqKey="Yuan B" first="Baohong" last="Yuan">Baohong Yuan</name>
<name sortKey="Zhang, Bobin" sort="Zhang, Bobin" uniqKey="Zhang B" first="Bobin" last="Zhang">Bobin Zhang</name>
</noCountry>
<country name="République populaire de Chine">
<region name="Guangdong">
<name sortKey="Yin, Hui" sort="Yin, Hui" uniqKey="Yin H" first="Hui" last="Yin">Hui Yin</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F82 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F82 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23480027
   |texte=   Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23480027" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020